Biotechnology · Nasdaq

VRTXVertex Pharmaceuticals Inc / Ma

Last close
$538.60 -0.7%
52-week range
$412.27 to $568.67
Market cap
$137B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$12.0B
+9% vs FY24
Net income
$3.95B
+838% vs FY24
Free cash flow
$3.19B
+504% vs FY24
Net cash
$6.61B
Cash $6.61B, debt $0.00

Stock price

+602% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on 1 of 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
34.7x
20.5x195x
71st percentile, above its median of 27.2x
Positive-earnings quarters only
Price / sales
10.5x
6.6x17.7x
48th percentile, below its median of 10.7x
EV / EBITDA
29.7x
14.5x897x
58th percentile, above its median of 24.4x
Price / free cash flow
42.6x
18.5x102x
78th percentile, above its median of 31.7x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
34.7x
Earnings yield
2.9%
Price / sales
10.5x
Price / book
6.5x
Price / operating cash flow
37.0x
EV / EBITDA
29.7x
EV / sales
10.4x
Free cash flow yield
2.3%

Profitability

Gross margin
85.5%
Operating margin
33.2%
Net margin
30.7%
Return on equity
19.0%
Return on capital
14.2%

Growth per year

Revenue, 3 years
+10.4%
Revenue, 5 years
+14.1%
Revenue, 9 years
+24.2%
EPS, 3 years
+6.1%

Balance sheet

Cash and investments
$6.30B
Total debt
$4.50B
Net cash
$1.81B
Debt / equity
0.22x
Current ratio
2.34x

Shares and dividend

Shares outstanding
254M
Share count, 5 years
-2.1%
Beta, 1 year
0.43
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $3.44B
RevenueNet income
Gross profitLatest quarter $2.91B
EBITDALatest quarter $782M
Margins85 / 21 / 19%
GrossOperatingNet
Earnings per shareLatest quarter $2.56
Cash flowLatest quarter $643M
OperatingCapexFree
Cash vs debtLatest quarter $6.30B
Cash and investmentsTotal debt
P/E historyNow 34.7x
P/E, median 27.2x dashed
P/S historyNow 10.5x
P/S, median 10.7x dashed

Where the revenue comes from

Manufactured Product Other went from 14% to 7% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

TRIKAFTAKAFTRIOALYFTREKManufactured Product OtherCASGEVYCollaborative and Royalty
FY22
86%14%
$8.93B
FY23
91%9%
$9.87B
FY24
93%
$11.0B
FY25
86%
$12.0B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
TRIKAFTAKAFTRIO$10.3B85.9%+1%
ALYFTREK$838M7.0%n/a
Manufactured Product Other$820M6.8%+5%
CASGEVY$116M1.0%+1,058%
Collaborative and Royalty$30.7M0.3%n/a

Biotechnology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ONC BeOne Medicines Ltd. $619B +33% 17.8%689x93.6x Not enough history
ABBV AbbVie Inc. $521B +11% 32.2%50.8x7.9x 72nd percentile
AMGN Amgen Inc $252B +8% 32.4%27.0x6.5x 78th percentile
GILD Gilead Sciences, Inc. $208B +7% -7.6%No earnings6.7x No earnings
VRTX Vertex Pharmaceuticals Inc / Ma $137B +10% 33.2%34.7x10.5x 71st percentile
MRNA Moderna, Inc. $90.4B +13% -116%No earnings35.8x No earnings

The company

Sector
Health Care
Industry
Biotechnology
CEO
Reshma Kewalramani
Founded
1989
Headquarters
Boston, MA
Fiscal year ends
December
Website
vrtx.com

What it does

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about VRTX.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 1,446 active funds. Crowd level: crowd building, 3 rising quarters.

Open the Smart money tab